Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Seroype A For Cervical Dystonia—An Assessment

A. Brashear
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Diagnosis of Cervical Dystonia Dystonia involves a lack of synergy of antagonist and agonist muscles, resulting in irregular and unco-ordinated movements. Clinically, focal dystonia occurs when the involuntary movements are isolated to one body part such as a limb (writer’s cramp), the larynx (spasmodic dysyphonia), or the eyes (blepharospasm). Cervical dystonia (CD), a form of focal dystonia involving the neck muscles, presents with abnormal postures of the neck. While typical CD presents with tilt (laterocollis), turn (torticollis), and/or pulling forward (anterocollis) or backward (retrocollis), any combination of these may be seen. In addition, some patients present with superimposed tremor and/or pain. While the involuntary movement is always part of CD presentation, in some patients pain can be the prominent complaint.
This paper references
10.1007/s004150050345
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency
K. Kessler (1999)
10.1517/14740338.4.2.241
The safety and tolerability of botulinum toxins for the treatment of cervical dystonia
A. Brashear (2005)
10.1212/01.wnl.0000198501.61063.66
Familial dopa-responsive cervical dystonia
S. Schneider (2006)
10.1002/MDS.870090216
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
10.1212/01.wnl.0000249310.25427.f2
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia
S. Cano (2006)
10.1016/j.pneurobio.2008.10.003
Primate models of dystonia
D. Guehl (2009)
10.1212/01.WNL.0000026474.12594.0D
The prevalence of primary dystonia in the general community
J. Müller (2002)
Classification of dystonia.
S. Fahn (1998)
10.1212/WNL.40.2.277
Botulinum toxin injections for cervical dystonia
J. Jankovic (1990)
10.1097/NRL.0b013e31816f2cdd
Clinical Comparisons of Botulinum Neurotoxin Formulations
A. Brashear (2008)
10.1002/mds.20025
Botulinum toxin treatment of occupational and focal hand dystonia
B. Karp (2004)
10.1212/01.wnl.0000249308.66959.43
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
J. Jankovic (2006)
10.1212/01.WNL.0000166030.05756.9F
A new screening tool for cervical dystonia
R. Saunders-Pullman (2005)
10.1212/WNL.46.4.1066
Botulinum toxin versus trihexyphenidyl in cervical dystonia
J. Brans (1996)
10.1212/WNL.41.7.1088
Cervical dystonia
J. Jankovic (1991)
10.1016/j.clineuro.2008.09.023
Quality of life in patients with focal dystonia
T. Pekmezović (2009)
The phenotypic spectrum of rapidonset dystoniaparkinsonism ( RDP ) and mutations in the ATP 1 A 3 gene
A Brashear (2007)
Safety and efficacy of NeuroBloc ( botulinum toxin type B ) in type Aresistant cervical dystonia
MF Brin (1999)
Safety and efficacy of NeuroBloc ( botulinum toxin type B ) in type Aresponsive cervical dystonia
A Brashear (1999)
10.1212/WNL.42.4.878
Botulinum toxin injection for spasmodic torticollis
C. Comella (1992)
10.1212/01.wnl.0000267425.51598.c9
Minimum incidence of primary cervical dystonia in a multiethnic health care population
C. Marras (2007)
10.1517/13543784.10.12.2191
Botulinum toxin type B: a new injectable treatment for cervical dystonia
A. Brashear (2001)
10.1212/01.WNL.0000035630.12515.E0
Diagnostic criteria for dystonia in DYT1 families
S. Bressman (2002)
Cervical dystonia: clinical findings and associated movement disorders, Neurology, 1991;41:1088–91
J Jankovic (1991)
10.1002/MDS.870130318
Comparison of acute‐ and delayed‐onset posttraumatic cervical dystonia
D. Tarsy (1998)
10.1002/1097-4598(200011)23:11<1752::AID-MUS12>3.0.CO;2-U
Utility of an EMG mapping study in treating cervical dystonia
J. V. van Gerpen (2000)
10.1055/S-2001-13123
The botulinum toxins in the treatment of cervical dystonia.
A. Brashear (2001)
10.1212/01.wnl.0000253188.76092.06
Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers
C. W. Hess (2007)
10.1093/BRAIN/AWL340
The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene.
A. Brashear (2007)
10.1212/WNL.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
A. Brashear (1999)
10.1093/BRAIN/121.11.2053
The natural history of tardive dystonia. A long-term follow-up study of 107 cases.
V. Kiriakakis (1998)
10.1111/j.1468-1331.2008.02196.x
Increased basal‐ganglia activation performing a non‐dystonia‐related task in focal dystonia
M. Obermann (2008)
10.1097/00002508-200211001-00002
Therapeutic Use of Botulinum Toxins: Background and History
P. Setler (2002)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
10.1002/mds.1226
Cervical dystonia severity scale reliability study
C. O'brien (2001)
10.1212/01.wnl.0000311389.26145.95
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review)
D. Simpson (2008)
10.1136/jnnp.64.1.13
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®
W. Poewe (1998)
10.1002/mds.20403
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study
D. Truong (2005)
Botulinum toxin type B versus type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, non-inferiority trial, Mov Disord, 2008;23:510–17
EJ Pappert (2008)
Botulinum treatment of strabismus in children.
A. B. Scott (1989)
10.1016/S1474-4422(06)70547-6
The diagnosis of dystonia
Howard L. Geyer (2006)
10.1212/01.WNL.0000142962.11881.26
Capturing the true burden of dystonia on patients
S. Cano (2004)
10.1002/mds.20670
Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia
I. M. Skogseid (2005)
10.1002/mds.20873
An open‐label trial of levetiracetam for treatment of cervical dystonia
D. Tarsy (2006)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, Neurology, 1999;53:1431–8
MF Brin (1999)
10.1002/MDS.870130130
Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
A. Brashear (1998)
10.1016/S0140-6736(94)90153-8
Dose standardisation of botulinum toxin
EricR. First (1994)
Epidemiology of dystonia in Rochester, Minnesota.
J. Nutt (1988)
Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance, Neurology, 1992;42:878–82
CL Comella (1992)
Botulinum toxin injections for cervical dystonia, Neurology, 1990;40:277–80
J Jankovic (1990)
10.1212/01.WNL.0000163767.99354.C3
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R. Benecke (2005)
Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
J. Slawek (2007)
10.1002/mds.21597
An open trial of levetiracetam for segmental and generalized dystonia
S. Hering (2007)
10.1136/jnnp.72.5.608
What are the determinants of quality of life in people with cervical dystonia?
Y. Ben-Shlomo (2002)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1002/mds.21724
Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial
E. Pappert (2008)
10.1002/mds.22157
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
M. Brin (2008)
10.1212/01.wnl.0000183055.81056.5c
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia
C. Comella (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar